3:18 PM
 | 
Oct 11, 2017
 |  BC Extra  |  Preclinical News

Team identifies HIF2A as liver disease target

A paper published in Nature Medicine by researchers at the National Cancer Institute and colleagues identified intestinal endothelial PAS domain protein 1 (HIF2A; HIF-2alpha; EPAS1) as a promising target to treat hepatic steatosis. The findings suggest a new indication for small molecule HIF2A inhibitors including PT2385 from Peloton Therapeutics Inc. (Dallas, Texas), which was used in the study.

Researchers identified that HIF2A had increased expression in distal ileum patient biopsies from obese individuals compared with non-obese individuals. When the researchers examined high-fat...

Read the full 421 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >